Please ensure Javascript is enabled for purposes of website accessibility

Is Cell Therapeutics Roaring Back?

By Dave Williamson – Updated Apr 7, 2017 at 12:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Finally, some good news for Cell Therapeutics, which has had a tough go of it ever since it pulled its application for lead non-Hodgkin's lymphoma drug Pixantrone even before a Food and Drug Adminstration advisory committee had a go at it. The drug had previously received a 9-0 vote against it (and subsequent rejection), although it's fared better through the European approval process.

As a welcome turnaround, company shares are up 18% today after receiving orphan drug status for brain cancer drug Opaxio. If approved, the drug could have seven years of exclusivity, although it still has phase 3 trials to pass.

Given Cell Therapeutics' weak balance sheet and management's history of dilution, health care analyst Dave Williamson recommends staying away from this one despite the good news. For the full story, be sure to check out the video below.

While you can make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long-term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, and also reveal some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Dave Williamson and Max Macaluso have no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.